TrialJournal of translational medicine2017

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.

Nora Sundahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.